People receiving certain chemotherapy could get prescribed scalp cooling covered by large-group plans starting in 2027, and by Medi-Cal when federal approval and funding allow.
Large-group health plans and insurers must cover prescribed scalp cooling for people receiving chemotherapy that can cause hair loss. Only FDA-cleared devices or systems qualify, and regular cost sharing may apply.
Medi-Cal will cover prescribed, FDA-cleared scalp cooling for eligible patients receiving certain chemotherapy, subject to medical necessity and utilization controls. Coverage depends on federal approval and available federal funding.
Large-group plans and insurers must cover prescribed scalp cooling. This covers large-group health care service plans and large-group health insurance policies. The device or system must be cleared by the FDA, and a health care provider must prescribe it to reduce hair loss linked to chemotherapy. Cost sharing may apply, but it cannot be less favorable than cost sharing for oncology supportive care under the same coverage. This rule does not apply to specialized health plans or specialized health insurance policies. Medi-Cal managed care is covered under the separate Medi-Cal provision. The requirement applies to a large-group contract or policy issued, amended, or renewed on or after January 1, 2027.
Medi-Cal must cover prescribed scalp cooling, subject to medical necessity and utilization controls. This applies to Medi-Cal beneficiaries receiving chemotherapy that can cause hair loss. The device or system must be cleared by the FDA and prescribed to reduce hair loss linked to chemotherapy. Implementation must follow federal law and depends on necessary federal approvals and federal funding being available without jeopardy. The provision takes effect only to the extent necessary federal approvals have been obtained and federal funding is available without being jeopardized.
No hearings or votes scheduled.